Access the full text.
Sign up today, get DeepDyve free for 14 days.
Jerry Call, Yu Wang, Denisse Montoya, Norman Scherzer, M. Heinrich (2019)
Survival in advanced GIST has improved over time and correlates with increased access to post-imatinib tyrosine kinase inhibitors: results from Life Raft Group RegistryClinical Sarcoma Research, 9
Call et al. Clin Sarcoma Res (2019) 9:7 Clinical Sarcoma Research https://doi.org/10.1186/s13569-019-0117-2 Open Access CORREC TION Correction to: Survival in advanced GIST has improved over time and correlates with increased access to post-imatinib tyrosine kinase inhibitors: results from Life Raft Group Registry 1* 1 1 1 2 Jerry W. Call , Yu Wang , Denisse Montoya , Norman J. Scherzer and Michael C. Heinrich Author details Correction to: Clin Sarcoma Res (2019) 9:4 1 2 Life Raft Group, 155 Route 46 West, Suite 202, Wayne, NJ 07470, USA. Port- https ://doi.org/10.1186/s1356 9-019-0114-5 land VA Health Care System and Knight Cancer Institute, Oregon Health & The legends for Figs. 3 and 5 of the article [1] incor - Science University, Portland, OR, USA. rectly refer to an “all others group”. The corrected legends should read: The original article can be found online at https ://doi.org/10.1186/s1356 9-019-0114-5. Fig. 3 Exploratory analyses of the impact of sunitinib on overall survival. a OS 2nd line, the “No sunitinib” group Publisher’s Note may or may not have had sunitinib later. b OS 2nd line, Springer Nature remains neutral with regard to jurisdictional claims in pub- the “Never sunitinib” group excludes patients that had lished maps and institutional affiliations. sunitinib at a later time. Fig. 5 OS 3rd line, the “Never regorafenib” group excludes patients that had regorafenib at a later time. Regorafenib improved overall survival by 11.9 months in Reference 3rd line treatment compared to best supportive care with 1. Call JW, Wang Y, Montoya D, Scherzer NJ, Heinrich MC. Survival in other TKI’s and excluding no treatment as best support- advanced GIST has improved over time and correlates with increased ive care. Patients that had regorafenib in any treatment access to post-imatinib tyrosine kinase inhibitors: results from Life Raft Group Registry. Clin Sarcoma Res. 2019;9:4. https ://doi.org/10.1186/s1356 line were excluded from the “Never regorafenib” group. 9-019-0114-5 A high percentage of patients in “Regorafenib” group were still alive at last follow-up (censored), suggesting an even greater benefit might be possible. Analysis limited to patients reporting progression in 2nd line. *Correspondence: jcall@liferaftgroup.org Life Raft Group, 155 Route 46 West, Suite 202, Wayne, NJ 07470, USA Full list of author information is available at the end of the article © The Author(s) 2019. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creat iveco mmons .org/licen ses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creat iveco mmons .org/ publi cdoma in/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Clinical Sarcoma Research – Springer Journals
Published: May 7, 2019
You can share this free article with as many people as you like with the url below! We hope you enjoy this feature!
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.